ONWARD Medical Introduces New Share Listing
ONWARD Medical N.V., a leader in medical technology, primarily focused on spinal cord stimulation, has exciting news regarding its next steps in growth. The company has published a prospectus for the admission of 10 million new ordinary shares, valued at EUR 0.12 each. This private placement, aimed at institutional investors, signifies a strategic move to secure additional funding to bolster its operations and innovations.
Prospectus Approval and Share Details
The listing prospectus, which has received approval from the Netherlands Authority for the Financial Markets, indicates that pricing and allocation have already been finalized. This proactive approach illustrates ONWARD's commitment to transparency and regulatory compliance while extending its capital base to further develop its groundbreaking spinal injury therapies.
A Focus on Innovation and Development
As a company dedicated to revolutionizing treatment for spinal cord injuries, ONWARD Medical has consistently prioritized research and development. Their flagship product, ARC Therapy™, represents a culmination of over a decade of rigorous scientific inquiry and clinical trials. It's designed to restore movement and independence for individuals with spinal cord injury, demonstrating the company's mission to change lives through technological advancement.
Strategic Importance of ARC Therapy™
ARC Therapy™ is a targeted approach to spinal cord stimulation, adaptable to various delivery mechanisms including the ARC-IM® and ARC-EX® platforms. By integrating with brain-computer interface (BCI) technology through the ARC-BCI™ platform, ONWARD has established a unique method that enables thought-driven movement restoration for patients affected by spinal injuries.
Clinical Trials and Regulatory Advances
The effectiveness of ARC Therapy™ has been showcased in global clinical studies, particularly the Up-LIFT trial. Significant improvements in upper limb functionality were recorded, leading to the submission of regulatory clearance to the FDA for the ARC-EX® System in the United States. Efforts are also underway for regulatory submissions in Europe, evidencing ONWARD's expansive approach to international market access.
Headquarters and Global Presence
Headquartered in Eindhoven, ONWARD Medical operates from several strategic locations around the globe, including a dedicated Science and Engineering Center in Lausanne, along with an office in Boston. This diverse setup facilitates an innovative environment for their research teams, promoting collaboration and knowledge sharing.
Connecting with the Community
As ONWARD Medical continues to innovate and expand its reach, they remain engaged with communities and stakeholders. Interested parties can learn more by visiting the company's website, where updates on their developments and impact on spinal cord injury treatment are regularly shared. For inquiries, potential investors and media representatives are encouraged to reach out through their respective channels.
Frequently Asked Questions
What is the main goal of the new share listing by ONWARD Medical?
The primary goal is to raise capital for advancing their spinal cord injury therapies and expand their operational capabilities.
How does ARC Therapy™ work?
ARC Therapy™ utilizes spinal cord stimulation to restore movement and independence in individuals affected by spinal cord injuries.
Where is ONWARD Medical headquartered?
ONWARD Medical is headquartered in Eindhoven, Netherlands, with additional facilities in Switzerland and the United States.
What recent advancements has ONWARD made in clinical trials?
The company recently achieved significant results in the Up-LIFT trial, demonstrating improved upper limb function in spinal cord injury patients.
How can I get in touch with ONWARD Medical?
Contact information for inquiries can be found on their website, where interested individuals can also explore their latest updates and developments.
